Clinical trials: Pregnancy in Diabetic
Diabetic Nephropathies, Hyperhomocysteinemia
The Effect of Folic Acid Administration in the Progression of Microalbuminuria
The development of diabetic nephropathy has been linked to several genetic polymorphisms, including those related with homocysteine metabolism such as the methylenetetrahydrofolate reductase (MTHFR)and the…
- Trial name
- NCT00737126
- Testing
- Folic acid
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Diabetic Kidney Disease
Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine
Background: Diabetic kidney disease (DKD) is chronic and often progresses to kidney failure,heart disease and premature death. Unfortunately, the best medical therapies available for DKD today are ultimately unable to prevent its…
- Trial name
- PROMISE (NCT02011178)
- Testing
- Optimal medical treatment and surgery, Optimal medical treatment
- Where
- 2 sites in Sweden, Switzerland
- Sponsor
- Karolinska Institutet
Diabetic Ketoacidosis, Acute Kidney Injury
Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.
Diabetic ketoacidosis (DKA), a severe complication of diabetes mellitus (DM), is the leading cause of hospitalization, morbidity and mortality in patients with DM (1).
- Trial name
- NCT05867797
- Volunteers
- 100 people
- Sponsor
- Sohag University
Heart Failure, Hypertension, Pulmonary
Measurement of Endothelial Function and Cardiac Output: New Methods
The main purpose of this study is to analyse test-retest-reliability of functional quantification of endothelial dysfunction through puls-amplitude-tonometry in patients with heart failure with preserved/reduced ejection…
- Conditions
- Heart Failure, Hypertension, Pulmonary, Hypertension, Diabetic Nephropathies
- Trial name
- NCT02299960
- Testing
- Endo-PAT, NICOM
- Where
- Germany
- Volunteers
- 101 people
- Sponsor
- Charite University, Berlin, Germany
Macrosomia, Fetal, Gestational Diabetes Mellitus in Pregnancy
New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs.
- Trial name
- GLYCAGEST (NCT06048510)
- Testing
- Pregnant women
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Bordeaux
Type 2 Diabetes Mellitus, Cardiovascular-Kidney-Metabolic Syndrome
Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes
Type 2 diabetes (T2D) is a principal driver of cardiovascular-renal-metabolic (CKM) syndrome, where metabolic, renal, and cardiac dysfunction accelerate disease progression.
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular-Kidney-Metabolic Syndrome, Diabetic Kidney Disease
- Trial name
- CKM-T2D (NCT07854990)
- Testing
- clinical and laboratory CKM staging evaluation
- Where
- Egypt
- Volunteers
- 231 people
- Sponsor
- Assiut University
Hyperglycemia in Pregnant Diabetic Patients
Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients
Our objective is to assess whether pre-treatment with a fixed dose of insulin, based on weight, given to pregnant patients with gestational or preexisting diabetes receiving betamethasone can provide adequate glycemic control.
- Trial name
- NCT01875107
- Testing
- insulin pre-treatment
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Gestational Diabetes Mellitus in Pregnancy
Glycated Albumin Combined With Body Composition for Gestational Diabetes Mellitus Prediction
This study is going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis.
- Trial name
- NCT04550806
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Diabetes Mellitus, Diabetic Nephropathy
Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes
The purpose of this study is to determine whether a new investigational drug, pirfenidone, will be an effective therapy for diabetic patients with kidney dysfunction.
- Trial name
- NCT00063583
- Testing
- Pirfenidone
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Sharma, Kumar, M.D.
Diabetic Nephropathy, Diabetic Retinopathy
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
This is a prospective, multicenter, randomized, double blind, placebo-controlled and a prospective observational study. This study will be conducted at 15 study centers in various European countries.
- Trial name
- PRIORITY (NCT02040441)
- Testing
- Spironolactone, Standard care
- Where
- 15 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,777 people
- Sponsor
- Peter Rossing
Type 2 Diabetes, Diabetic Nephropathy
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
Angiotensin type-1 receptor (AT1R) blockers (ARBs) have been recognized recently as regulators of glucose and lipid metabolism in adipocytes and adipose tissue.Moreover telmisartan and irbesartan have been recognized recently as…
- Trial name
- NCT00361023
- Testing
- losartan
- Volunteers
- 25 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT02015780
- Testing
- Fasiglifam, Antihyperglycemic therapy
- Where
- 30 sites in United States, Bulgaria and 5 more
- Sponsor
- Takeda
Birth Weight, Fetal Growth Retardation
Automated Fetal Weight Estimation: A Multicenter Validation Using Fractional Limb Volume
This trial is a collaborative study between 4 sites worldwide. A total of 600 research subjects will be enrolled. We will investigate the validity of using 5D Limb Volume software to improve on estimated fetal weight predictions…
- Conditions
- Birth Weight, Fetal Growth Retardation, Fetal Weight, Fetal Macrosomia
- Trial name
- NCT03002246
- Testing
- Ultrasound Examination
- Volunteers
- 330 people
- Sponsor
- Baylor College of Medicine
Type 2 DM, Type 2 DM /Diabetic Nephropathy
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes.
- Conditions
- Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
- Trial name
- SIGNAL (NCT06954090)
- Testing
- Semaglutide, 1.34 mg/mL, Finerenone Oral Tablet, Dapagliflozin (DAPA)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Steno Diabetes Center Copenhagen
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
- Trial name
- NCT01464320
- Testing
- ABT-614
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Pregnancy, Pregnancy in Diabetes
Exploration of the Lipid Metabolism During the Diabetic Pregnancies
Justification: Intrauterine exposure to type 1 or type 2 diabetes increase the risk of macrosomia (35 % to 50 % versus 10 % in general population) despite a good glycemic control.
- Conditions
- Pregnancy, Pregnancy in Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- DIAMANT (NCT00639964)
- Testing
- blood tests, diet questionnaire, umbilical cord blood collect
- Where
- France
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Diabetes Mellitus in Pregnancy, Gestational Diabetes
Biomarkers During Pregnancy
This study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women.
- Trial name
- NCT04108455
- Testing
- Specimens Collected
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Washington University School of Medicine
Diabetic Nephropathies
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
The MEDiaN study aims to examine the state of fuel metabolism in participants with diabetic nephropathy (DN) before and after the use of the sodium-glucose transport protein 2 inhibitor (SGLT-2i) empagliflozin.
- Trial name
- (MEDiaN) (NCT03933956)
- Testing
- Empagliflozin 10 MG
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Singapore General Hospital